Home›Bosutinib

Bosutinib

Route: Oral

5 interactions on record

Bosutinib has 5 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Levoketoconazole, Cyp3a Inducers, Itraconazole. Patients taking Bosutinib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 5
Contraindicated: 1
Major: 4

Contraindicated (1)

Bosutinib + Levoketoconazole— Concomitant use is contraindicated due to increased risk of QT prolongation and torsades de pointes.

Major (4)

Bosutinib + Cyp3a Inducers— Avoid concomitant use. Decreases bosutinib Cmax and AUC, which may reduce BOSULIF efficacy.
Bosutinib + Itraconazole— Axitinib Bosutinib Cabazitaxel Cabozantinib Ceritinib Cobimetinib Crizotinib Dabrafenib Dasatinib Docetaxel Ibrutinib La…
Bosutinib + Mao Inhibitors— Avoid concomitant use. Increases bosutinib Cmax and AUC, which may increase risk of toxicities.
Bosutinib + Voriconazole— Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabr…

Bosutinib + Levoketoconazole⛔Contraindicated

Concomitant use is contraindicated due to increased risk of QT prolongation and torsades de pointes.

Bosutinib + Cyp3a Inducers⚠️Major

Avoid concomitant use. Decreases bosutinib Cmax and AUC, which may reduce BOSULIF efficacy.

Bosutinib + Itraconazole⚠️Major

Axitinib Bosutinib Cabazitaxel Cabozantinib Ceritinib Cobimetinib Crizotinib Dabrafenib Dasatinib Docetaxel Ibrutinib Lapatinib Nilotinib Olaparib Pazopanib Sunitinib Trabectedin Trastuzumab-emtansine Vinca alkaloids Avoid use during and 2 weeks after itraconazole treatment.

Bosutinib + Mao Inhibitors⚠️Major

Avoid concomitant use. Increases bosutinib Cmax and AUC, which may increase risk of toxicities.

Bosutinib + Voriconazole⚠️Major

Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Avoid concomitant use of VFEND.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.